盗U空投钓鱼页面模板|【唯一TG:@heimifeng8】|Telegram账号盗号云控破解技术✨谷歌搜索留痕排名,史上最强SEO技术,20年谷歌SEO经验大佬✨New fluorescent drug detects tumors three times more accurately
Russian researchers have developed a new fluorescent diagnostic agent based on the carboxylate derivative of chlorine, and this agent significantly surpasses existing analogues in selectivity of action, reports Naked Science.
The drug can selectively accumulate in tumor cells, providing high contrast of tumor tissues compared to healthy ones, which opens up new opportunities for early detection of cancer.
The new chlorine derivative has a three-fold higher selectivity for accumulation in tumor tissue compared to chlorine e6. In addition, due to the long-term preservation of the fluorescence of the carboxylate derivative of chlorine in the tumor, it becomes possible to carry out fluorescent diagnostic interventions for a long time, which is relevant for intraoperative fluorescence navigation.
The drug is activated by light with a wavelength of 660 nm, which penetrates tissue to a depth of 15 millimeters, enabling the visualization of tumors that were previously difficult to detect. In tests on mice with Lewis lung carcinoma (LLC), the fluorescence contrast was 11—versus 3.5 for chlorine e6.
It is likely that the high contrast and tropism of this diagnostic agent towards tumor cells is due to the presence of a polar fragment in its structure, which can form zwitterionic forms similar to amino acids.
“The use of the fluorescent diagnostic agent we developed enables to increase the level of selectivity of accumulation, as well as the fluorescence contrast when performing fluorescence diagnostics in oncology,” emphasized Professor Mikhail Grin, Doctor of Chemical Sciences.